Clinical impact of mean pulmonary arterial pressure after balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension
In patients with CTEPH after BPA, an mPAP of <30 mm Hg was associated with a favourable prognosis, and patients with an mPAP of ≤20 mm Hg presented with better symptoms, exercise capacity, right ventricular function and more withdrawal from oxygen therapy and pulmonary vasodilators. The BPA treatment goal may require individual adaptation.
Authors
- Hiroki Horinouchi (ORCID: https://orcid.org/0000-0002-5305-7823)
- Hiroya Hayashi (ORCID: https://orcid.org/0000-0003-3053-0670)
- Akihiro Tsuji (ORCID: https://orcid.org/0000-0002-3280-6119)
- Ryo Takano (ORCID: https://orcid.org/0000-0003-4078-3479)
- Takeshi Ogo (ORCID: https://orcid.org/0000-0003-1180-9262)
- Kenichi Tsujita (ORCID: https://orcid.org/0000-0002-4314-259X)
- Tatsuo Aoki (ORCID: https://orcid.org/0000-0002-6140-0417)
- Akiyuki Kotoku (ORCID: https://orcid.org/0000-0002-7887-0941)
- Teruo Noguchi (ORCID: https://orcid.org/0000-0001-5372-4932)
- Takatoyo Kiko (ORCID: https://orcid.org/0000-0003-4298-088X)
- Hiroyuki Endo (ORCID: https://orcid.org/0000-0003-4531-2991)
- Ryotaro Asano (ORCID: https://orcid.org/0000-0003-0303-6546)
- Jin Ueda (ORCID: https://orcid.org/0000-0002-3942-8499)
- Mitsumasa Akao
- Shinya Fujisaki (ORCID: https://orcid.org/0009-0006-4477-2637)
- Tetsuya Fukuda (ORCID: https://orcid.org/0000-0001-7579-0674)
- Naruhiro Nishi
Institutions
- National Cerebral and Cardiovascular Center (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Open Heart
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/openhrt-2025-003532
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Amgen
- Pfizer
- AstraZeneca
- Takeda Pharmaceutical Company
- Boston Scientific Corporation
- Kowa Company
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Daiichi-Sankyo
- Novo Nordisk
- Otsuka Pharmaceutical
- Ono Pharmaceutical
- Novartis Pharma
- Pfizer Japan
- MSD K.K.
- Bayer Yakuhin
- Novo Nordisk Pharma
- Daiichi Sankyo Europe